Please assess the completion status of the following clinical trial:

Trial Title: Randomized Clinical Trial, Open, Multicenter Parallel, no Suspension Inferiority Prophylactic Treatment With Valganciclovir in Kidney Transplant CMV-seropositive Cellular Immunity to Develop CD8 + CMV-specific Treatment After Induction Thymoglobulin.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Renal transplant CMV-Seropositive~* CD8+ Tcell CMV especific pretransplant (CMV-reactive quantiferon pretrasplant)~* \> 18 years (adult)~* Receiving Thymoglobulin induction therapy~* Receiving Valganciclovir prophylaxis~* Written informed consent for trial entry~Exclusion Criteria:~* Multivisceral transplants including kidney-pancreas.~* HIV-infected Patients~* Patients who can not comply with the monitoring protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- New profilaxis (Type: EXPERIMENTAL): Prophylaxis is discontinued when the patient developed CMV-specific cellular immunity.
- Profilaxis recommended by TTS (Type: ACTIVE_COMPARATOR): Valganciclovir prophylaxis until day +90 as recommended by the International Consensus document of the TTS.

Based on this trial design, predict the completion outcome and termination type (if applicable).